Study identifies drug with a positive effect on heart failure patients with preserved ejection fraction

By | August 28, 2021
Until now, patients with heart failure with preserved ejection fraction – the most common type of heart failure in the elderly – have had no access to evidenced-based treatments. For the first time, a large clinical trial led by Prof. Dr. Stefan Anker from Charité – Universitätsmedizin Berlin has identified a drug which has a distinctly positive effect on prognosis. In patients affected by this type of heart failure, the drug – empagliflozin – reduces the risk of hospitalization or cardiovascular death by 21 percent. The results of this research have been published in the New England Journal of Medicine.